SPCS2

Across TCGA pan-cancer cohorts, SPCS2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SPCS2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SPCS2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SPCS2 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LUAD, LSCC, and HNSC are the cancer types where SPCS2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPCS2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	+0.595	<.001	9	view →
LSCC	Female	All	+0.726	<.001	8	view →
HNSC	All	All	+0.293	.001	8	view →
PDAC	Female	All	−1.353	<.001	6	view →
CCRCC	All	II,III,IV	+0.220	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SPCS2–LUAD

Open the LUAD breakdown →